The necessity of animal testing is a sad one for the process of drug discovery, but theres seemingly no good alternative to mice, even though theyre not particularly accurate human analogues. Quris claims to have the first real option in its combination of AI with data from a patient on a chip that provides remarkably robust testing and automation, all at a considerably lower cost no mouse required.
The company has raised a $9 million seed round to go from pilot to production, and an all-star team of backers and advisors are a promising indicator that the approach has fundamental merit.
The basic idea makes perfect sense: build a better small-scale simulation of a human body and use it to gather data that a machine learning system can easily interpret. Its easier said than done, of course, but no sooner did researchers say it than Quris started doing it.
The Israel-based companys approach builds on a major study at Harvard concerning the use of so-called organs on a chip. These systems, still relatively new but established in the field, use a small amount of stem cell-derived tissue (organoids) as a test bed for drugs or treatments providing a good idea of how, for example, a human liver might respond to a combination of substances.
What the Harvard researchers found is that by linking multiple organ-on-a-chip systems (like liver to kidney to heart cells), you end up with a surprisingly effective simulation of the human body. Theres nothing like the real thing, of course, but this serial organoid system or patient on a chip could be a real alternative to mouse testing; thats still the most common way of seeing how a treatment affects a complete organ system, despite the fact that substances that pass the mouse phase only succeed in human tests about 10% of the time.
CEO and co-founder Isaac Bentwich said that as soon as that study came out, he and his colleagues recognized the potential and started working on what needed to be done in terms of engineering and AI in order to turn this from an experimental system to a scalable product. Its not just a mouse replacement, either its a (relatively) inexpensive method to do limited human testing without the humans, and without the uncertainty of mice.
A rendering of how the full-scale automated chip on chip device will look. Image Credits: Quris
Say youre a pharma company, said Bentwich in an interview. Do you want to wait until youre at the brink of going to clinical testing to find out whether a molecule that looks good on paper is actually effective? You can make all the genomics discoveries you want, but it wont get you past mice experiments, where it fails 90% of the time. This lets you pick the winning horse before you go to the race.
Considering drug candidates can cost hundreds of millions to get to the clinical stage, its more than worth spending even a small fortune (think tens of millions) to weed out a few destined for failure. If the technique is accurate and indications are that it is then the risk is practically nil and it will pay for itself if even a single expensive dead end is avoided. In other words, Bentwich put it, this brings the fail early, fail cheap mentality of software to a domain where neither was really an option.
The Quris system uses what it calls a chip-on-chip technique, in other words multiple organoid systems (chips) in sequence (on another chip), but smaller and more efficient than state of the art lab systems by an order of magnitude. It would cost millions to run a hundred simulated humans the way Harvards researchers did it, but thousands to do so on Quriss system, which uses less raw biological material, can be automated and is accompanied by a well-trained machine learning model.
Thats the other aspect that Quris is playing up: that this unique set of data will drive a unique AI that understands and can help run and interpret the experiments. The AI is already being trained with existing and some upcoming drugs, learning what signals from the various sensors mean for the safety of the substance. That allows effective testing to be done with a handful of chips rather than, say, 500 mice.
The chips themselves arent all the same, either. By manipulating and selecting the stem cells and tissues carefully, different types of people and different conditions or phenotypes can be tested for. If a company has a drug that works well but causes side effects 10% of the time and they dont know why, testing against different genetic predispositions or complicating factors in an automated setting may be able to find out what genetic factors lead to those side effects.
Members of the Quris team work in a lab. Image Credits: Quris
Since the AI is aware of and cataloguing all this, it should get quite good at telling from a relatively small number of automated tests (think dozens, not thousands, and at a cost of thousands, not millions) whether a drug is a good candidate for human testing or not. Without the AI interpreting it, the data suddenly becomes a multi-PhD type of problem. But Bentwich was quick to note that they in no way anticipate eliminating the biological side and relying only on the AI. Its part of our philosophical and biological understanding that the AI has to work with a biological counterpart, he said.
Robert Langer, co-founder of Moderna, is on the scientific advisory board, and told TechCrunch in the same interview that he concurred, and expects this technique to be adopted quickly, but not necessarily by the naturally conservative larger pharma companies.
This does seem to be a very big opportunity, he said. Ive had similar ideas in other areas of chemistry, that you can use AI to make these predictions. It certainly wont replace testing but it narrows the possibilities, and my view is it would speed things up tremendously.
Its nice to have someone like Langer on your side (along with Nobel laureate Aaron Ciechanover), but Bentwich said that theyre relying more on their patent portfolio and first mover advantage to get a foot in the door. An agreement with the NY Stem Cell Foundation gives them special access to that organizations stem cell workflow.
There are two prongs to the business model. One is providing the service to a pharma company of screening their drug candidates, with payment contingent on the results proving to be accurate for example, a drug cleared by the system makes it to a given testing milestone as predicted. The other is to work on their own drugs; right now the company has a treatment for the Autism-linked Fragile X condition that it will be taking to clinical testing next year.
Bentwich pointed out that despite the proliferation of and investment in AI-powered drug discovery, few companies can claim to have a molecule resulting from their work entering clinical trials. This isnt because they arent doing what they claim, for instance identifying molecules with certain bioreactivity or a method to manufacture them efficiently, but rather because there are so many other steps in the long discovery, testing and approval process that the chance of making it through, while higher than it once was, is still very low.
The $9 million seed round funds us very well to finish the productization of the setup that we have, making it more efficient and automated, and testing the first hundred or thousand initial drugs to train the AI, Bentwich said. The round was led by Dr. Judith Richter and Dr. Kobi Richter, pioneers of cardiovascular intervention therapeutics, with participation from Moshe Yanai, a disruptive data-storage technology leader, and strategic angel investors, as the press release puts it. A distinct lack of institutional capital draw your own conclusions there.
Bentwichs vision for the company is part of his general vision of completely personalized medicine. If the cost of stem cells continues to drop (already it has gone from millions to thousands), it would open up entirely new markets.
Itll no longer be just doing expensive experiments for pharma companies. In five-10 years time this may well be what hundreds of millions of people are doing. If you think about it, its actually kind of barbaric how were living now, he said. You go to the pharmacist and they list the possible side effects, but you dont know for sure. What, are you the guinea pig? The answer is: yes, were all guinea pigs. But this is a first step away from that.
- Irving Weissman Laboratory | Institute for Stem Cell ... - December 4th, 2021
- Nine Things To Know About Stem Cell Treatments - A Closer ... - December 4th, 2021
- Regenerative Medicine & Stem Cell Therapy Las Vegas ... - December 4th, 2021
- World AIDS Day: is a cure for HIV finally in sight? - Thomson Reuters Foundation - December 4th, 2021
- New genetic technology for gene expression analysis of cancer cells - News-Medical.net - December 4th, 2021
- Stem Cell Therapy Restores Insulin Production in Patients with Type 1 Diabetes - MD Magazine - December 4th, 2021
- It takes guts to make a heart - EurekAlert - December 4th, 2021
- Appia Bio Announces Appointment of Irving Weissman, MD, and Mark Exley, PhD, to Scientific Advisory Board - BioSpace - December 4th, 2021
- The Intramural Research Program at the Abu Dhabi Stem Cell Center (ADSCC) Signs a Letter of Intent to Collaborate with the Division of Intramural... - December 4th, 2021
- TScan Therapeutics to Host a Virtual Event to Discuss Highlights from the 63rd ASH Annual Meeting and Exposition - GlobeNewswire - December 4th, 2021
- Genomic Testing Cooperative to Present data at the American Society of Hematology Meeting on its Proprietary Machine Learning Approaches for RNA... - December 3rd, 2021
- Cell Culture Media Market is predicted to grow from US$ 2.6 Bn in 2020 to over US$ 5.6 Bn by 2031 - PRNewswire - December 3rd, 2021
- Appia Bio Announces Appointment of Irving Weissman, MD, and Mark Exley, PhD, to Scientific Advisory Board - PRNewswire - December 3rd, 2021
- Treatment Tricks Cancer Cells Into Changing Their Identity To Eliminate Them - Technology Networks - December 3rd, 2021
- Soumit K. Basu MD PhD is recognized by Continental Who's Who - The Wellsboro Gazette - December 3rd, 2021
- Report of Placebo-Controlled Clinical Trial Evaluating MultiStem Cell Therapy for Acute Respiratory Distress Syndrome Published in Intensive Care... - November 30th, 2021
- Restorative treatments for erectile dysfunction arent proven to work. Men pay thousands anyway. - The Philadelphia Inquirer - November 30th, 2021
- Talaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001 in Individuals with a Severe Form of Scleroderma - Yahoo Finance - November 30th, 2021
- Letter to the editor | In support of Hakeem Jefferson and the Early Career Black Faculty Group - The Stanford Daily - November 30th, 2021
- Jasper Therapeutics: Advancing Cures With HSC Transplants And Safer Prior Conditioning - Seeking Alpha - November 30th, 2021
- Immunomic Therapeutics Announces Collaboration With iOncologi - BioSpace - November 28th, 2021
- How drugs are reviewed and approved in Canada - The Globe and Mail - November 27th, 2021
- JGC : Investment in two companies in the MSC regenerative medicine and digital therapeutics fields through CVC fund - marketscreener.com - November 27th, 2021
- Global Cell Therapy Manufacturing Market Report 2021, Featuring Key Players KBI Biopharma, Waisman Biomanufacturing, Merck and Thermo Fisher... - November 27th, 2021
- Digital twins for predictive oncology will be a paradigm shift for precision cancer care - Nature.com - November 27th, 2021
- From tummy tucks to facelifts: Pet plastic surgery is happening in Ohio - NewsNation Now - November 27th, 2021
- Susanna Park inducted as holder of Roth Endowed Chair for Discovery, Education and Patient Care - UC Davis Health - November 24th, 2021
- Global Cell Therapy Markets Report 2021-2030: Cell Therapy Markets According to Therapeutic Areas, Technologies, & Companies - PRNewswire - November 24th, 2021
- Research Developments in the Treatment of Advanced Kidney Cancer - liherald - November 24th, 2021
- The Expanding Role of Interferons in Myeloproliferative Neoplasms - Targeted Oncology - November 24th, 2021
- InGeneron Publishes Significant Support for the Existence of Naturally Pluripotent Stem Cells in All Organs in the Adult Body - Galveston County Daily... - November 24th, 2021
- UoH start-up ties up with GenepoweRx for personalizing medical procedures - United News of India - November 24th, 2021
- BioRestorative Therapies Enters into Letter of Intent with PRC Clinical - BioSpace - November 22nd, 2021
- FDA Action Alert: Takeda, Aadi and Fennec - BioSpace - November 22nd, 2021
- New MedHouse Location Opens in West Palm Beach, Powered by R3 Health: Popular Concierge Membership Social Wellness and Biohacking Club Welcomes New... - November 22nd, 2021
- Researchers use model of hypothalamus to implicate genes associated with sleep, BMI, puberty, and more - EurekAlert - November 21st, 2021
- Orchard Therapeutics Announces New England Journal of Medicine Publication of Interim Proof-of-concept Study Results of OTL-203 for Hurler Syndrome -... - November 21st, 2021
- Gene Therapy May Reverse Hurler Syndrome, a Rare and Severe Illness in Kids - HealthDay - November 18th, 2021
- Braeden Lichti - Investing in Precision Medicine to Yield New Treatments for Neurodegenerative Diseases - PRNewswire - November 18th, 2021
- Orchard Therapeutics Announces New England Journal of Medicine Publication of Interim ... - The Bakersfield Californian - November 18th, 2021
- Diabetes breakthrough: Revolutionary stem cell technique treated 'severe' disease in study - Daily Express - November 18th, 2021
- French biotech CellProthera welcomes three exceptional talents to its executive management team - Business Wire - November 18th, 2021
- FDA Approves Merck's KEYTRUDA (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery - Business... - November 18th, 2021
- BioBridge Global continues history of innovation with umbilical cord collection and processing under cGMP standards for further manufacture -... - November 18th, 2021
- PhD Studentship, Cartilage Regenerative Medicine job with UNIVERSITY OF SOUTHAMPTON | 271677 - Times Higher Education (THE) - November 16th, 2021
- Behind the FDA Approval: Belumosudil for Chronic Graft Versus Host Disease - Targeted Oncology - November 16th, 2021
- Dr. Nathan Newman Recognized as a Professional of the Year for 2021 by Strathmore's Who's Who Worldwide - PR.com - November 16th, 2021
- A second HIV patient may have been 'cured' of infection without stem cell treatment, in extremely rare case - CNN - November 16th, 2021
- miRNA-based therapeutics to treat Glioblastoma at Johns Hopkins Medical Institute in Baltimore - Open Access Government - November 16th, 2021
- New dates announced for global scientific conference recruited to Memphis by UT Health Science Center and Tennessee Institute of Regenerative Medicine... - November 13th, 2021
- Regenerative Medicine Market to reach US$ 25,959.5 Mn by end of 2028, Says Coherent Market Insights - PRNewswire - November 13th, 2021
- ASCO Reading Room | CAR T-Cell Therapy in Hematologic Malignancies | MedPage Today - MedPage Today - November 13th, 2021
- This Week at FDA: CDRH and Endologix leaks, OTC monograph reform, and more - Regulatory Focus - November 13th, 2021
- Always Ready: A military man's motto on service and cancer - Yale School of Medicine - November 13th, 2021
- 100 years after insulin treatment was invented, researchers hope to ditch needles once and for all - CBC.ca - November 13th, 2021
- These 5 Things Can Cause Your Hip to Collapse Eat This Not That - Eat This, Not That - November 13th, 2021
- Athersys Reports Updates on Timing for Japan ARDS and Stroke Programs From Healios KK - GuruFocus.com - November 13th, 2021
- Putting the move back in movement - Scope - Scope - November 11th, 2021
- Revolutionizing the way we treat lack of blood flow diseases by using stem cell therapy - InvestorIntel - November 11th, 2021
- Creative Medical Technology Holdings Announces Implementation of Reverse Stock Split in Preparation for Planned Uplisting to The Nasdaq Capital Market... - November 11th, 2021
- It takes a village (of cells) to heal the intestine - Baylor College of Medicine News - November 11th, 2021
- Fate Therapeutics Announces Abstract Highlighting FT538 and FT573 Programs Selected for Presentation at SITC 2021 Annual Meeting Press Conference -... - November 11th, 2021
- CAR T-cell therapy: Hear from a Canadian patient - CTV News - November 9th, 2021
- UM teams to research under-studied aspects of COVID-19 - UM Today - November 9th, 2021
- COVID Booster Eligibility: Who Can Get the Third Vaccine Dose Now? - NBC10 Boston - November 9th, 2021
- He cant cure his dad. But a scientists research may help everyone else. - The Indian Express - November 9th, 2021
- Hoth Therapeutics Inks API and Drug Product Contracts with WuXi STA to Advance Manufacturing of HT-KIT Cancer Therapeutic - Yahoo Finance - November 9th, 2021
- MS in Stem Cell Biology and Regenerative Medicine - November 7th, 2021
- Institute for Stem Cell & Regenerative Medicine ... - November 7th, 2021
- Stem-cell niche - Wikipedia - November 7th, 2021
- Stem Cell Network - November 7th, 2021
- This is such an important moment: how stem cell research ... - November 7th, 2021
- Experts gain insights into pathomechanisms of dilated cardiomyopathy - News-Medical.Net - November 7th, 2021
- Updates in Therapies of Relapsed and Refractory Follicular Lymphoma - Cancer Network - November 7th, 2021
- Totipotent Stem Cell - an overview | ScienceDirect Topics - November 7th, 2021
- Editas Medicine to Present Data Demonstrating Progress Towards Transformative Gene Editing Medicines for the Treatment of Hemoglobinopathies and... - November 5th, 2021
- Parkinson's gene therapy restores responses to dopamine-boosting drug in mouse models - FierceBiotech - November 5th, 2021
- Treatment Sequencing Could Change With Complementary Combinations and CAR T Options in B-ALL - OncLive - November 5th, 2021
- Shockwave therapy brings new healing opportunities for heart attack patients and hope for people with spinal cord injuries - WDRB - November 5th, 2021
- Clade Therapeutics Raises $87 Million Series A Financing to - GlobeNewswire - November 5th, 2021